ADVENTRX PHARMACEUTICALS INC
Form 8-K
September 12, 2006

Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): September 12, 2006
ADVENTRX Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware	**1-15803**	**84-1318182**
(State or Other Jurisdiction of Incorporation)	(Commission File No.)	(IRS Employer Identification No.)

6725 Mesa Ridge Road, Suite 100
San Diego, CA 92121
(Address of Principal Executive Offices and Zip Code)
N/A
(Former name or former address if changed since last report)
Registrant s telephone number, including area code: **(858) 552-0866**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

Table of Contents

Item 7.01. Regulation FD Disclosure.

Evan M. Levine, Chief Executive Officer of Adventrx Pharmaceuticals, Inc. (Adventrx), will be presenting the information contained in the slides attached as Exhibit 99.1 to this Current Report on Form 8-K (this Report) on September 12, 2006 at the ThinkEquity Partners LLC 4th Annual Growth Conference at The Ritz Carlton Hotel, San Francisco.

The information in this Report, including the slides attached hereto as Exhibit 99.1, is being furnished pursuant to this Item 7.01 and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933 or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Report.

By filing this Report and furnishing this information, Adventrx makes no admission as to the materiality of any information in this Report. The information contained in the slides is summary information that is intended to be considered in the context of Adventrx filings with the Securities and Exchange Commission (the SEC) and other public announcements that Adventrx makes, by press release or otherwise, from time to time. Adventrx undertakes no duty or obligation to publicly update or revise the information contained in this Report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

Adventrx cautions you that information included in the slides attached hereto as Exhibit 99.1 that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Adventrx that any of its plans, including its anticipated milestones, will be achieved on time or at all. Actual results may differ materially from those set forth in this report due to the risks and uncertainties inherent in Adventrx business, including, without limitation: the potential for CoFactor® and Adventrx other product candidates to receive regulatory approval for one or more indications on a timely basis or at all; other difficulties or delays in development, testing, manufacturing and marketing of and obtaining regulatory approval for CoFactor® or Adventrx other product candidates; the results of pending clinical trials for CoFactor® or Adventrx other product candidates; unexpected adverse side effects or inadequate therapeutic efficacy of CoFactor® or Adventrx other products that could delay or prevent regulatory approval or commercialization, or that could result in recalls or product liability claims; the scope and validity of patent protection for CoFactor® and Adventrx other product candidates; the market potential for fluoropyrimidine biomodulators and other target markets, and Adventrx ability to compete in those markets; the potential to attract a strategic partner and the terms of any related transaction; Adventrx ability to raise sufficient capital to meet its anticipated goals and milestones; and other risks detailed in Adventrx Annual Report on Form 10-K, filed with the SEC on March 16, 2006, Adventrx Quarterly Report on Form 10-Q, filed with the SEC on August 9, 2006, and other periodic filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Adventrx undertakes no obligation to revise or update the slides attached hereto to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The list of exhibits called for by this Item is incorporated by reference to the Index to Exhibits filed with this report.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ADVENTRX Pharmaceuticals, Inc.

Dated: September 12, 2006

By: /s/ Evan M. Levine

Name: Evan M. Levine
Title: Chief Executive Officer

Table of Contents

INDEX TO EXHIBITS

99.1	ThinkEquity Partners LLC 4th Annual Growth Conference Presentation Slides dated September 12, 2006.